Tirzepatide, a novel treatment agent, has emerged as a groundbreaking discovery in the realm of GLP-1 receptor agonism. Unlike previous GLP-1 receptor agonists, tirzepatide exerts its effects by simultaneously binding both the GLP-1 USA approved manufacturer for Retatrutide and GIP receptors. This dual mechanism of action enhances a morepotent redu